Product news from the 10/21/05 News Brief

Share this article:

The FDA approved the expanded use of GlaxoSmithKline's Havrix (hepatitis A vaccine, inactivated) for the prevention of hepatitis A in children aged 12 months and older. Havrix was previously approved by the FDA for use in children ages two through 18 years. This expanded indication will allow healthcare practitioners to vaccinate younger children against hepatitis A with Havrix.

Esprit Pharma acquired exclusive North American rights to Estrasorb (estradiol topical emulsion) from Novavax. A topical emulsion form of the naturally occurring hormone beta-estradiol 17, Estrasorb is the first prescription topical emulsion for estrogen therapy.

Upsher-Smith Laboratories introduced new Vandazole (metronidazole vaginal gel, 0.75 percent) for treatment of bacterial vaginosis in non-pregnant patients.

Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.